Core Viewpoint - The company is actively engaging in academic collaborations with well-known hospitals and universities in China to establish a market-oriented industry-university-research cooperation model, which lays a solid foundation for the rapid industrialization of new products [1] Group 1 - The company collaborates with notable institutions such as the Chinese People's Liberation Army General Hospital (301 Hospital), Chongqing University, Shandong University, and Shenzhen University [1]

Market Overview - The electronic chemicals sector experienced a decline of 0.53% on August 26, with Tongyu New Materials leading the drop [1] - The Shanghai Composite Index closed at 3868.38, down 0.39%, while the Shenzhen Component Index closed at 12473.17, up 0.26% [1] Stock Performance - Notable gainers in the electronic chemicals sector included: - Sanfu New Materials (688389) with a closing price of 73.20, up 10.46% [1] - Fivotech (688371) with a closing price of 23.27, up 6.35% [1] - Anji Technology (610889) with a closing price of 166.40, up 4.41% [1] - Conversely, significant decliners included: - Tongyu New Materials (301630) with a closing price of 199.23, down 8.75% [2] - Siquan New Materials (301489) with a closing price of 175.16, down 8.29% [2] - Shanghai Xinyang (300236) with a closing price of 53.75, down 3.98% [2] Capital Flow - The electronic chemicals sector saw a net outflow of 786 million yuan from institutional investors, while retail investors contributed a net inflow of 623 million yuan [2] - The capital flow for specific stocks showed: - Fivotech (688371) had a net inflow of 35.21 million yuan from institutional investors [3] - Anji Technology (610889) had a net inflow of 20.25 million yuan from institutional investors [3] - Tongyu New Materials (301630) experienced a significant net outflow of 49.42 million yuan from institutional investors [3]

证券代码：688389 证券简称：普门科技 公告编号：2025-064 深圳普门科技股份有限公司 关于召开2025年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 会议召开时间：2025年9月2日（星期二）上午10:00-11:00 ● 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） ● 会议召开方式：上证路演中心网络互动 ● 投资者可于2025年8月26日（星期二）至9月1日（星期一）16:00前登录 上证路演中心网站首页点击"提问预征集"栏目或通过深圳普门科技股份有限公 司（以下简称"公司"）邮箱bod@lifotronic.com进行提问。公司将在说明会上 对投资者普遍关注的问题进行回答。 （三）会议召开方式：上证路演中心网络互动 三、参加人员 公司董事长刘先成先生，董事、总经理胡明龙先生，董事、副总经理曾映先 生，董事、财务总监王红女士，独立董事蔡翘梧先生、杨光辉 ...

深圳普门科技股份有限公司 关于自愿披露取得医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 深圳普门科技股份有限公司（以下简称"公司"）于近期收到了1个广东省 药品监督管理局颁发的《中华人民共和国医疗器械注册证（体外诊断试剂）》， 具体情况如下： 证券代码：688389 证券简称：普门科技 公告编号：2025-063 上述注册证的取得仅代表公司相关产品获得国内市场准入资格，产品上市后 的实际销售情况取决于未来市场的推广效果，目前尚无法预测上述产品对公司未 1 / 2 来业绩的具体影响。 敬请投资者理性投资，注意投资风险。 特此公告。 深圳普门科技股份有限公司董事会 一、医疗器械注册证的具体情况 | 产品名称 | 注册 | 注册证 | 注册证 | | 预期用途 | | --- | --- | --- | --- | --- | --- | | | 分类 | 编号 | 有效期至 | | | | β-人绒毛膜促性腺激素 （β-HCG | | 粤械注准 | | 年 | 用于体外定量测定人血清或血 浆中β-人绒毛 ...

Policy Developments - The National Health Commission and five other departments released measures to enhance the experience of family doctor contract services, focusing on improving service quality and health management for residents [2] Drug and Device Approvals - Novo Nordisk's Wegovy (semaglutide 2.4mg) received FDA approval for treating metabolic-associated fatty liver disease (MASH) with moderate to severe liver fibrosis, which is expected to boost sales [3] - Yiling Pharmaceutical's new traditional Chinese medicine, "Children's Lianhua Qinggan Granules," has received acceptance for its new drug registration application [4] - Pumen Technology obtained a medical device registration certificate for its high-sensitivity cardiac troponin I testing kit, which aids in diagnosing myocardial infarction [5] Financial Reports - Ping An Good Doctor reported a 19.5% increase in revenue to approximately 2.502 billion yuan and a net profit increase of 136.8% to 134 million yuan for the first half of the year [6] - Weier Pharmaceutical's revenue decreased by 2.1% to 674 million yuan, with a net profit decline of 7.77% to 72.77 million yuan in the same period [7] Capital Market Activities - Jianzhijia plans to sell its Qinhuangdao logistics center assets for approximately 24 million yuan, which does not constitute a related party transaction [8] - Gilead Sciences announced a placement of 52.4 million shares at a discount of about 9.9%, with expected net proceeds of approximately 467.69 million HKD, primarily for clinical trials related to obesity [9] Industry News - The National Disease Control Bureau reported a decline in new cases of Chikungunya fever in Foshan, with daily cases dropping from over 600 to below 100, indicating effective control measures [10] - A breakthrough study from Harvard University demonstrated the ability to induce human pluripotent stem cells to initiate meiosis, offering new hope for addressing infertility [11] Public Sentiment Alerts - Baiotai announced that Xinyu Qiheng reduced its stake by 0.78%, selling 3.2169 million shares and raising approximately 105 million yuan [12]

风险提示：本文所提及个股仅作客观陈述，不构成投资建议。市场有风险，投资需谨慎。 8月19日公司公告称，获得广东省药监局颁发的《医疗器械注册证》，产品为高敏心肌肌钙蛋白I测定试 剂盒。该试剂采用电化学发光法，用于检测心肌损伤标志物，当心肌受损时能快速检测外周血中cTnI浓 度变化。 资金流向方面，当日主力资金净流出1352.27万元，近五日累计净流出2395.26万元。 普门科技8月19日报收14.49元，较前一交易日下跌0.11元，跌幅0.75%。当日成交量为60910手，成交金 额达0.89亿元，总市值62.09亿元。 该公司主营业务为医疗器械制造，产品涵盖体外诊断、治疗与康复等领域。2024年财报显示，医疗器械 业务占营收比重达98.56%。2025年一季度实现营业收入2.15亿元，净利润5368万元。 ...

Core Viewpoint - Pumen Technology has received a medical device registration certificate for its high-sensitivity cardiac troponin I (hs-cTnISTAT) assay kit from the Guangdong Provincial Drug Administration [1] Company Summary - The product is classified as an in vitro diagnostic reagent and utilizes electrochemical luminescence technology [1]

Group 1 - Pumen Technology (SH 688389, closing price: 14.49 yuan) announced on August 19 that it has received a Medical Device Registration Certificate from the Guangdong Provincial Drug Administration for its product "High-Sensitivity Cardiac Troponin I Test Kit" [2] - For the year 2024, Pumen Technology's revenue composition is as follows: 98.56% from medical devices and 1.44% from other businesses [2]

证券代码：688389 证券简称：普门科技 公告编号：2025-062 深圳普门科技股份有限公司 关于自愿披露取得医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 深圳普门科技股份有限公司（以下简称"公司"）于近期收到了1个广东省 药品监督管理局颁发的《中华人民共和国医疗器械注册证（体外诊断试剂）》， 具体情况如下： 一、医疗器械注册证的具体情况 | 产品名称 | | | | | 注册 | 注册证 | 注册证 | | 预期用途 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | 分类 | 编号 | 有效期至 | | | | 高 敏 心 肌 （hs-cTnI STAT）测定试 | 肌 | 钙 | 蛋 | 白 I | 类 II | 粤械注准 | 2030 | 年 | 用于体外定量测定人血清或血 浆中肌钙蛋白 （I cTnI）的含量。 | | | | | | | | 20252401126 | 月 日 8 | ...

格隆汇8月19日丨普门科技(688389.SH)公布，近期收到了1个广东省药品监督管理局颁发的《中华人民 共和国医疗器械注册证（体外诊断试剂）》，产品名称：高敏心肌肌钙蛋白I（hs-cTnISTAT）测定试剂 盒（电化学发光法）。心肌肌钙蛋白I（cTnI）是临床诊断中高度敏感的心肌损伤标志物。当心肌发生 损伤后，细胞中多种形式的心肌肌钙蛋白（包括I-C复合物、I-T-C三聚体以及游离肌钙蛋白I、游离肌钙 蛋白T）释放到血液中，导致外周血中cTnI浓度迅速上升。大量临床研究表明，在急性心肌梗死发病后 4-10小时，心肌肌钙蛋白会出现在血清中，其浓度在12-48小时达到峰值，并在随后4-10天内维持升高状 态。心肌肌钙蛋白水平的动态变化，是鉴别急性和慢性心肌损伤的关键，同时可以辅助诊断心肌梗死。 ...